Mirae Asset Global Etfs Holdings Ltd. Avidity Biosciences, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.9 Billion
- Q4 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 144,570 shares of RNA stock, worth $4.67 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
144,570
Previous 179,490
19.46%
Holding current value
$4.67 Million
Previous $8.24 Million
49.0%
% of portfolio
0.01%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding RNA
# of Institutions
257Shares Held
110MCall Options Held
341KPut Options Held
366K-
Price T Rowe Associates Inc Baltimore, MD11MShares$357 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$305 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$279 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.11MShares$262 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$256 Million3.76% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.68B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...